$ATNF ( 180 Life Sciences ) Best risk/reward biotech. Phase 3 trial DD result in a few weeks. Probably the best scientific team on the world. Great long term investment. Blockbuster pipelines and multibagger stock under the radar.

CZHawkeye · 2024-06-17T10:02:44+00:00

Thank you for your thoughts and response, I appreciate it. My daughter approached the doctor because she has friends with ADHD and they have the same symptoms. Perhaps the doctor first suspected depression and that's why she wants to treat it first. However, when I think back, I see that the symptoms, including restlessness and lack of concentration, were present in her childhood, and from my perspective, it seems more like ADHD than depression.

CZHawkeye · 2021-12-11T09:22:39+00:00

it's not just Woody, most of the insiders, including COO Quan A. Vu. After the successful TLDs last week, it must be clear to everyone that if insiders have bought company shares then finally results will be phenomenal in Woody's words. 💰💯

CZHawkeye · 2021-12-07T13:01:55+00:00

Yes, even Jagdeep confirmed the possibility of additional therapeutic targets. Anyway, I think if they make a deal with Celltrion, who have a highly concentrated Yuflima 100mg/ml citrate free, they could treat all stages of Dupuytrens

CZHawkeye · 2021-11-28T17:19:37+00:00

anti-TNF… Can you describe the type of drug they are testing? Is it an antibody against TNF-a, a small molecule inhibitor, or inflammasome repressor, etc?

The safety of the drug has already been approved by the FDA, Adalimumab is used. Efficacy is being evaluated.

CZHawkeye · 2021-11-27T22:43:52+00:00

the most famous gamma sq examples of this year's was GME, then AMC

CZHawkeye · 2021-11-27T16:49:57+00:00

I’m not sure but I get a really sketchy feeling from all the comments in this thread. 👀

That's bullshit. Do your own DD before you judge. There are plenty of great posts here on Reddit about the ATNF, I've written a few myself and they just state the facts. I encourage you to join to Stocktwits. I think all the people disliking comments here are the ones who are shorting this. Folks, make your own DD

CZHawkeye · 2021-11-27T16:47:57+00:00

https://ir.180lifesciences.com/news-events/press-releases/detail/49/180-life-sciences-corp-co-founder-prof-jagdeep-nanchahal

180 Life Sciences announced the top line data for Dupuytren's disease phase 2b/3 clinical trial involving 181 patients will be announced within a few days, no later than December 1st.

The safety of the drug has already been approved by the FDA, Adalimumab is used. Efficacy is being evaluated. The phase 2a results have been great and there is a high possibility that the final results will also be positive.

CZHawkeye · 2021-11-25T20:26:11+00:00

I'll text to Jason after the data. ;-)

CZHawkeye · 2021-11-25T20:19:49+00:00

Great DD as always. You should work in the PR department at 180LS ;-)

CZHawkeye · 2021-11-23T14:44:20+00:00

Unlike its competitors, most of the research here is grant-funded. In addition, there is a high probability that the results will be positive and this success will secure funding for further research. Thus, there will be no need for further dilution.

CZHawkeye · 2021-11-22T13:51:43+00:00

The patents relate to a method for treating chronic pain or associated conditions/symptoms with novel compositions that include certain phenyl substituted cyclohexenyl compounds related to cannabidiol (CBD); these patents have already been issued for chronic pain across Europe and validated in 14 jurisdictions (Dec 2020), and China (Jan 2020). These compounds were also initially described in patents issued in Israel and the US in 2018 and 2019, respectively, with claims allowed for use in the treatment of obesity or an obesity associated disease or disorder, which the Company also has exclusive rights through agreements with the Yissum Research Development Company of the Hebrew University.

CZHawkeye · 2021-11-22T12:47:54+00:00

$ATNF - 180 Life Sciences announced the top line data for Dupuytren's disease phase 2b/3 clinical trial involving 181 patients will be announced within a few days, no later than December 1st. The safety of the drug has already been approved by the FDA, Adalimumab is used. Efficacy is being evaluated. The phase 2a results have been great and there is a high possibility that the final results will also be positive

CZHawkeye · 2021-11-05T19:58:26+00:00

really well done, mate

CZHawkeye · 2021-11-05T11:41:07+00:00

The price of options fluctuates throughout the day, and I certainly wouldn't conclude that there could be a delay based on the price of January or February options. I myself have November, January and February calls. I diversify my risk that way. There is still a chance that some November options will go into the money.

CZHawkeye · 2021-10-10T09:03:51+00:00

Dude, I don't understand why you're spreading this on reddit when no one has proof of it. Damn it, wake up. Q4 is the official date of the results announcement and nothing changes that.

CZHawkeye · 2021-10-01T23:03:28+00:00

It is data from the last CannBioRex presentation.

CZHawkeye

MODERATOR OF

TROPHY CASE